AMGN241004P312500
- 0.68
- 0.000.00%
Amgen Newsroom
Barclays Adjusts Price Target on Amgen to $315 From $300, Maintains Equalweight Rating
DBS Maintains Amgen(AMGN.US) With Buy Rating
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Amgen Analyst Ratings
Cantor Fitzgerald Initiates Amgen(AMGN.US) With Buy Rating, Announces Target Price $405
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
RBC Capital Sticks to Its Buy Rating for Amgen (AMGN)
Amgen Analyst Ratings
Baird Reiterates Underperform on Amgen, Maintains $215 Price Target
Baird Maintains Amgen(AMGN.US) With Sell Rating, Maintains Target Price $215
Leerink Partners Maintains Amgen(AMGN.US) With Hold Rating
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $344 to $381
TD Cowen Sticks to Its Buy Rating for Amgen (AMGN)
Regeneron Downgraded at Leerink After Amgen's Court Win; Truist Defends
Redburn Atlantic Adjusts Amgen Price Target to $200 From $180, Maintains Sell Rating
Oppenheimer Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Amgen (AMGN) Gets a Buy From Jefferies
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344